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Abnormal Ubiquitination of 
Ubiquitin-Proteasome System in 
Lung Squamous Cell Carcinomas
Xianquan Zhan and Miaolong Lu
Abstract
Ubiquitination is an important post-translational modification. Abnormal 
ubiquitination is extensively associated with cancers. Lung squamous cell carci-
noma (LUSC) is the most common pathological type of lung cancer, with unclear 
molecular mechanism and the poor overall prognosis of LUSC patient. To uncover 
the existence and potential roles of ubiquitination in LUSC, label-free quantitative 
ubiquitomics was performed in human LUSC vs. control tissues. In total, 627 ubiq-
uitinated proteins (UPs) with 1209 ubiquitination sites were identified, including 
1133 (93.7%) sites with quantitative information and 76 (6.3%) sites with qualitative 
information. KEGG pathway enrichment analysis found that UPs were significantly 
enriched in ubiquitin-mediated proteolysis pathway (hsa04120) and proteasome 
complex (hsa03050). Further analysis of 400 differentially ubiquitinated proteins 
(DUPs) revealed that 11 subunits of the proteasome complex were differentially 
ubiquitinated. These findings clearly demonstrated that ubiquitination was 
widely present in the ubiquitin-proteasome pathway in LUSCs. At the same time, 
abnormal ubiquitination might affect the function of the proteasome to promote 
tumorigenesis and development. This book chapter discussed the status of protein 
ubiquitination in the ubiquitin-proteasome system (UPS) in human LUSC tissues, 
which offered the scientific data to elucidate the specific molecular mechanisms of 
abnormal ubiquitination during canceration and the development of anti-tumor 
drugs targeting UPS.
Keywords: lung squamous cell carcinoma, ubiquitination, ubiquitinated protein 
(UP), differentially ubiquitinated protein (DUP), ubiquitin-proteasome system 
(UPS)
1. Introduction
Ubiquitination is one of the important protein post-translational modifica-
tions (PTMs) in human body, in which ubiquitin, a 76-amino-acid protein with a 
molecular weight of 8.5 KDa, is covalently attached its C-terminus to the ε-amino 
group of the substrate protein lysine residue through a multi-step enzymatic reac-
tion cascade catalyzed by ubiquitin-activating enzymes (E1), ubiquitin-conjugating 
enzymes (E2), and ubiquitin ligases (E3) [1]. As substrate proteins commonly 
contain multiple lysine residues, there are a variety of ubiquitination forms such as 
monoubiquitination (only one ubiquitin attached to a protein), multiubiquitination 
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(several lysine residues of substrate proteins were tagged with single ubiquitin), 
and polyubiquitination (a polyubiquitin chain is derived from subsequent ubiquitin 
covalently attached to lysine residues or N-terminus of the former ubiquitin) [2]. 
It is worth noting that the ubiquitin itself also has seven lysine residues to greatly 
complicate the topology of the polyubiquitin chain. Different ubiquitination forms 
perform different functions, such as monoubiquitination or multiubiquitination 
has been shown to be required for the entry of certain cargo proteins into vesicles at 
different stages of the secretory/endocytic pathway, while lysine-48 ubiquitin chain 
is mainly related to proteasome [3]. Like other PTMs, ubiquitination is a reversible 
reaction, and there are over 100 deubiquitination enzymes that regulate this process 
[4]. Ubiquitination coordinates with deubiquitination to regulate a broad host of 
cellular processes, including DNA repair, cell differentiation, signal transduction, 
enzymatic activity regulation, assembly of multiprotein complexes, protein traf-
ficking, and autophagy [5]. Therefore, abnormal ubiquitination is associated with 
many diseases, including cancer, neurodegenerative disease, infection, and immune 
disorders [6]. Considering the importance of ubiquitination in tumorigenesis, 
different components of ubiquitin-proteasome system could be regarded as targets 
for discovery of anti-tumor drugs. With the application of first and second thera-
peutic proteasome inhibitors, such as Bortezomib (FDA has approved it for multiple 
myeloma and mantle cell lymphoma) [7] and Carfilzomib (FDA has approved it for 
relapsed and refractory multiple myeloma) [8], more and more anti-tumor drugs 
targeting UPS have been developed and approved by FDA, such as thalidomide, 
lenalidomide, and pomalidomide for treatment of multiple myeloma [9, 10].
Lung squamous cell carcinoma (LUSC) is a common type of lung cancer without 
a clear molecular mechanism. Currently, surgery, radiation, and chemotherapy 
have made significant advances in lung cancer treatment, especially targeted drug 
therapy; for example, epidermal growth factor receptor (EGFR) mutation or 
EML4-ALK fusion-based targeted therapies have improved the survival time of 
patients with lung adenocarcinoma (LUAD). However, targeted therapy and early-
stage diagnosis are still a big clinical challenge in LUSC patients [11]. Although 
FGFR1 amplification and DDR2 mutation have been nominated as “druggable” 
targets in LUSC patients, the clinical efficacies of the corresponding drugs are still 
under clinical trials [12, 13]. Considering that abnormal ubiquitination will lead to 
the occurrence of a variety of tumors and the widespread clinical applications of 
anti-tumor drugs for the ubiquitin-proteasome pathway in recent years, the study 
of quantitative ubiquitinomics in LUSC tissues may provide the direction for the 
development of biomarkers and new targeted drugs.
High-resolution liquid chromatography in combination with tandem mass 
spectrometry (LC-MS/MS) has been used as a power tool for large-scale identifica-
tion of various PTMs such as ubiquitination, phosphorylation, acetylation, and 
N-glycosylation [14]. The challenge of the use of LC-MS/MS to identify endogenous 
ubiquitination sites on a large scale is the fact that ubiquitination is a low abundance 
event in vivo and the size of the modification itself. The common strategy to identify 
low-abundance ubiquitinations in a proteome is that the extracted protein sample is 
firstly digested with trypsin to form tryptic peptide mixture, then the commercially 
specific anti-K-ε-GG antibodies are used to preferentially enrich ubiquitinated 
peptides from tryptic peptide mixture before MS/MS analysis in recent years [15]. 
Anti-ubiquitin antibody (specific anti-K-ε-GG group)-based label-free quantifi-
cation coupled with LC-MS/MS has been used as an effective method to detect, 
identify, and quantify ubiquitinated proteins and ubiquitination sites, and more 
than 10,000 ubiquitination sites have been identified and quantified [16]. For lung 
cancer, ubiquitinomics is mainly carried out in lung cancer cells [17, 18], while 
the ubiquitinomics of fresh LUSC tissues is only reported recently in our research 
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group with label-free quantitative proteomics method and bioinformatics analysis 
to reveal the functions of ubiquitinome in predictive, preventive, and personalized 
medicine (PPPM) of LUSC [19].
This book chapter mainly reviewed ubiquitinated proteins (UPs) and dif-
ferentially ubiquitinated proteins (DUPs) in ubiquitin-proteasome-system (UPS) 
in LUSC, and emphasized the potential regulatory role of ubiquitination in UPS, 
which offers scientific data for further research on the regulatory mechanism of 
ubiquitination on UPS, the molecular mechanism of UPS abnormality in tumor 
development, and the development of anti-tumor drugs targeting UPS.
2. Materials and methods
2.1 Lung cancer tissues and protein extraction
Human LUSC tissues (n = 5) and tumor-adjacent control lung tissues (n = 5) were 
surgically removed from patients, immediately stored in liquid nitrogen (−196°C), 
and then stored in freezer (−80°C). Clinical characteristics of each sample were 
described previously [19]. LUSC tissues (750 mg, equally mixed 5 tumor tissues) 
and control tissues (750 mg, equally mixed 5 control tissues) were washed 5 times 
with 3 mL 0.9% NaCl to clean blood on the surface of the tissues. The washed tissues 
(LUSC; or controls) were homogenized with urea lysis buffer [2 M thiourea, 7 M 
urea, 1 mM protein inhibitor PMSF, and 100 mM dithiothreitol(DTT)], sonicated, 
and centrifuged (15,000 g, 20 min, and 4°C). The supernatant was the extracted 
protein sample. The protein content was tested with Brandford method. The detailed 
procedure of protein extraction was described previously [19].
2.2 Protein digestion and enrichment of ubiquitinated peptides
An amount of DTT (final concentration = 10 mM) was added to each extracted 
protein sample, which was mixed (600 rpm, 1.5 h, and room temperature). 
An amount of iodoacetamide (final concentration = 50 mM) was added to the 
DTT-treated protein sample, which was incubated (dark, 30 min). The uranyl 
acetate (UA) was diluted to 2 M with 50 mM Tris HCl buffer (pH 8.0) and added 
to each protein sample. An amount of trypsin was added to each protein sample 
(trypsin:protein = 1:50 at wt:wt), and then incubated (37°C, 15–18 h). A volume of 
10% trifluoroacetic acid (TFA; final concentration = 0.1%) was added, and pH was 
adjusted to ≤ 3 to stop digestion. Each tryptic peptide sample was purified with 
C18 cartridges and then lyophilized. The lyophilized tryptic peptides were resolved 
with 1.4 mL immunoaffinity purification (IAP) buffer that contained 50 mM NaCl, 
10 mM Na2HPO4, 50 mM MOPS/NaOH, and pH 7.2. The anti-K-ε-GG antibodies 
against ubiquitin remnant motif (K-ε-GG) (Cell Signal Technology) were used 
to enrich the ubiquitinated peptides, followed by purification with C18 STAGE 
Tips. The purified ubiquitinated peptide sample was used for MS/MS analysis. The 
detailed experimental procedure was described previously [19].
2.3 LC-MS/MS
The prepared ubiquitinated peptide sample was analyzed with LC-MS/MS in 
the Easy nLC and Q Exactive mass spectrometer (Thermo Scientific). The MS/MS 
data for each sample were used to search protein database using MaxQuant 1.5.3.17 
software to identify ubiquitinated proteins and ubiquitination sites and quantify the 
abundance of ubiquitination. The detailed procedure was described previously [19].
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2.4 Bioinformatics
For UPs and DUPs, DAVID software (version 6.8, https://david.ncifcrf.gov/) was 
used to carry out the gene ontology (GO) enrichment analysis, including cellular com-
ponents (CCs), molecular functions (MFs), and biological processes (BPs), and group 
those proteins into different functional clusters [20]. The statistically significant 
pathways were mined with the Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathway enrichment analysis. The KEGG online service tool KOBAS (http://kobas.cbi.
pku.cn) was used to annotate the KEGG database description of each protein [21].
3. Results and discussion
3.1 Proteomics analysis of lysine-ubiquitinated profile in LUSC
To identify protein lysine-ubiquitinated sites and quantify the level of 
ubiquitination in human LUSC tissues, proteins were extracted and digested 
into peptides with trypsin. Lysine-ubiquitinated peptides were immunoaffinity-
enriched with commercially specific anti-K-ε-GG antibodies and analyzed with 
high-resolution LC-MS/MS. In total, 1209 lysine-ubiquitinated sites in 627 unique 
proteins were identified. These proteins containing ubiquitinated lysine residues 
were defined as UPs. Figure 1 showed two representative MS/MS spectra of the 
ubiquitinated peptides 425ETNLDSLPLVDTHSK*R440 from vimentin (P08670; 
K* = ubiquitinated lysine residue) (Figure 1A), and 633RPVK*DGGGTNSITVR647 
from multidrug resistance-associated protein 1 (P33527; K* = ubiquitinated lysine 
residue) (Figure 1B). All other ubiquitinated sites and ubiquitinated proteins were 
identified with the same MS/MS method. The differentially ubiquitinated peptides 
were determined with amino acid sequences, ratio(tumor/control) > 2.0 or < 0.5, 
and p-value < 0.05. Proteins containing this type of ubiquitinated peptides were 
defined as DUPs. Totally, 400 DUPs with 654 ubiquitinated sites were identified in 
LUSC tissues vs. tumor-adjacent control lung tissues [19].
3.2  UPs and DUPs were significantly enriched in UPS-related biological 
processes and molecular functions in LUSC
GO functional enrichment analyses of 627 UPs and 400 DUPs were carried 
out according to BPs, MFs, and CCs. GO enrichment result-based cluster analysis 
grouped those UPs into seven clusters (Table 1), and DUPs into 10 clusters (Table 2).
Among GO enrichment results of 627 UPs, many biological processes, molecular 
functions, and cellular components related to UPS were significantly enriched, 
including negative regulation of ubiquitin-protein ligase activity involved in mitotic 
cell cycle, and positive regulation of ubiquitin-protein ligase activity involved in 
regulation of mitotic cell cycle transition in cluster 2, and proteasome-activating 
ATPase activity, positive regulation of proteasomal protein catabolic process, cyto-
solic proteasome complex, nuclear proteasome complex, and proteasome regula-
tory base complex in cluster 3 (Table 1). Interestingly, DUPs were also significantly 
enriched in the similar biological processes, molecular functions, and cellular 
components, including proteasome accessory complex, negative regulation of 
ubiquitin-protein ligase activity involved in mitotic cell cycle, positive regulation of 
ubiquitin-protein ligase activity involved in regulation of mitotic cell cycle transi-
tion, and protein polyubiquitination in cluster 2, and proteasome-activating ATPase 
activity, positive regulation of proteasomal protein catabolic process, cytosolic 
proteasome complex, nuclear proteasome complex, and proteasome regulatory 
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base complex in cluster 3 (Table 2). These findings clearly demonstrated that many 
ubiquitinated proteins were involved in UPS system, and differential ubiquitination 
occurred in UPS system in LUSC, implying that ubiquitination participated in the 
regulation of UPS, and abnormal ubiquitination might play an important role in the 
development of LUSC.
3.3 UPs involved in UPS-related molecular network alternations in LUSC
KEGG pathway network analysis of 627 UPs revealed 47 statistically significant 
ubiquitination-mediated signaling pathway alterations (P < 0.05 and FDR < 0.05) 
(Figure 2), among which were included two UPS-related pathways—ubiquitin-
mediated proteolysis pathway (hsa04120) and proteasome complex (hsa03050).
Ubiquitin-mediated proteolysis pathway showed the detailed process of protein 
ubiquitination, which involved multiple types of E1s, E2s, and E3s. This study found 
that one E1 (UBE1), two E2s (UBE2N, and UBE2O), and six E3s (ITCH, HUWE1, 
UBE4B, PML, CUL4A, and CUL5) were ubiquitinated in LUSC (Figure 3). These 
six E3s belonged to different subfamilies, in which ITCH and HUWE1 belonged to 
HECT type E3, UBE4B belonged to U-box type E3, PML belonged to single RING-
finger type E3, and both CUL4A and CUL5 belonged to multi subunit RING-finger 
type E3. E1s, E2s, and E3s are the important enzymes to catalyze the occurrence of 
ubiquitination in a protein. The ubiquitination of these enzymes definitely affects 
the quitination process of a protein. Currently, studies on these enzymes have 
focused on their roles in the ubiquitination process, and the effects of PTMs on these 
enzymes are poorly understood. There are relatively few studies on the ubiquitina-
tion of these nine enzymes. For example, ubiquitinated PML (P29590, identified 
in this study) was mediated by multiple E3s, leading to subsequent proteasomal 
degradation [22, 23]. Self-ubiquitination of ITCH (Q96J02, identified in this study) 
Figure 1. 
Representative MS/MS spectra of ubiquitinated peptides 425ETNLDSLPLVDTHSK*R440 from vimentin 
(P08670) (A) and 633RPVK*DGGGTNSITVR647 from multidrug resistance-associated protein 1 (MRP1) 
(P33527) (B). K* = ubiquitinated lysine residue. Reproduced from Lu et al. [19], with permission from Springer 
publisher open access article, copyright 2020.
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Category GO term p -value
Annotation cluster 1
GOTERM_MF_DIRECT Cadherin binding involved in cell-cell adhesion 1.43E-29
GOTERM_CC_DIRECT Cell-cell adherens junction 3.72E-29
GOTERM_BP_DIRECT Cell-cell adhesion 1.13E-23
Annotation cluster 2
GOTERM_BP_DIRECT Wnt signaling pathway, planar cell polarity pathway 5.78E-11
GOTERM_BP_DIRECT Regulation of cellular amino acid metabolic process 4.14E-09
GOTERM_BP_DIRECT Stimulatory C-type lectin receptor signaling pathway 4.43E-09
GOTERM_BP_DIRECT NIK/NF-kappa B signaling 1.37E-08
GOTERM_BP_DIRECT Tumor necrosis factor-mediated signaling pathway 2.96E-08
GOTERM_BP_DIRECT Negative regulation of ubiquitin-protein ligase activity 
involved in mitotic cell cycle
3.70E-08
GOTERM_BP_DIRECT Positive regulation of ubiquitin-protein ligase activity 
involved in regulation of mitotic cell cycle transition
9.13E-08
GOTERM_BP_DIRECT Anaphase-promoting complex-dependent catabolic 
process
1.52E-07
GOTERM_BP_DIRECT T cell receptor signaling pathway 9.74E-07
GOTERM_BP_DIRECT Positive regulation of canonical Wnt signaling pathway 1.13E-06
GOTERM_BP_DIRECT Negative regulation of canonical Wnt signaling pathway 1.57E-05
Annotation cluster 3
GOTERM_CC_DIRECT Proteasome regulatory particle, base subcomplex 1.29E-08
GOTERM_CC_DIRECT Nuclear proteasome complex 1.70E-08
GOTERM_CC_DIRECT Cytosolic proteasome complex 1.21E-07
GOTERM_MF_DIRECT Proteasome-activating ATPase activity 1.70E-07
GOTERM_BP_DIRECT Positive regulation of RNA polymerase II 
transcriptional preinitiation complex assembly
3.45E-06
GOTERM_MF_DIRECT TBP-class protein binding 3.27E-05
GOTERM_BP_DIRECT Positive regulation of proteasomal protein catabolic 
process
9.97E-05
Annotation cluster 4
GOTERM_BP_DIRECT SRP-dependent cotranslational protein targeting to 
membrane
3.56E-08
GOTERM_BP_DIRECT Viral transcription 7.74E-08
GOTERM_BP_DIRECT Nuclear-transcribed mRNA catabolic process, 
nonsense-mediated decay
1.92E-07
GOTERM_BP_DIRECT Translational initiation 6.60E-06
GOTERM_CC_DIRECT Ribosome 3.32E-05
GOTERM_MF_DIRECT Structural constituent of ribosome 1.68E-03
Annotation cluster 5
GOTERM_CC_DIRECT Haptoglobin-hemoglobin complex 9.95E-05
Annotation cluster 6
GOTERM_BP_DIRECT Nucleotide-excision repair, DNA damage recognition 6.40E-04
Annotation cluster 7
GOTERM_CC_DIRECT Hemoglobin complex 4.59E-03
Table 1. 
The functional categories of 627 ups, identified with GO enrichment analysis.
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Category GO term p-value
Annotation cluster 1
GOTERM_MF_DIRECT Cadherin binding involved in cell-cell adhesion 3.11E-18
GOTERM_CC_DIRECT Cell-cell adherens junction 2.24E-17
GOTERM_BP_DIRECT Cell-cell adhesion 1.23E-13
Annotation cluster 2
GOTERM_CC_DIRECT Proteasome accessory complex 4.60E-12
GOTERM_BP_DIRECT Antigen processing and presentation of exogenous 
peptide antigen via MHC class I, TAP-dependent
1.59E-11
GOTERM_BP_DIRECT Regulation of cellular amino acid metabolic process 3.49E-09
GOTERM_BP_DIRECT NIK/NF-kappaB signaling 5.35E-09
GOTERM_BP_DIRECT Negative regulation of ubiquitin-protein ligase activity 
involved in mitotic cell cycle
1.27E-08
GOTERM_BP_DIRECT Stimulatory C-type lectin receptor signaling pathway 1.85E-08
GOTERM_BP_DIRECT Positive regulation of ubiquitin-protein ligase activity 
involved in regulation of mitotic cell cycle transition
2.83E-08
GOTERM_BP_DIRECT Anaphase-promoting complex-dependent catabolic 
process
4.43E-08
GOTERM_BP_DIRECT Tumor necrosis factor-mediated signaling pathway 8.37E-08
GOTERM_BP_DIRECT Positive regulation of canonical Wnt signaling pathway 1.04E-07
GOTERM_BP_DIRECT T cell receptor signaling pathway 2.37E-07
GOTERM_BP_DIRECT Fc-epsilon receptor signaling pathway 4.90E-07
GOTERM_BP_DIRECT Protein polyubiquitination 7.65E-07
GOTERM_BP_DIRECT Negative regulation of canonical Wnt signaling pathway 4.36E-06
Annotation cluster 3
GOTERM_CC_DIRECT Proteasome regulatory particle, base subcomplex 4.88E-10
GOTERM_CC_DIRECT Nuclear proteasome complex 1.00E-09
GOTERM_CC_DIRECT Cytosolic proteasome complex 7.28E-09
GOTERM_MF_DIRECT Proteasome-activating ATPase activity 1.54E-08
GOTERM_BP_DIRECT Positive regulation of RNA polymerase II transcriptional 
preinitiation complex assembly
3.41E-07
GOTERM_MF_DIRECT TBP-class protein binding 2.10E-06
GOTERM_BP_DIRECT Positive regulation of proteasomal protein catabolic 
process
1.05E-05
GOTERM_BP_DIRECT Protein catabolic process 1.41E-04
Annotation cluster 4
GOTERM_BP_DIRECT Regulation of ventricular cardiac muscle cell action 
potential
1.11E-03
GOTERM_MF_DIRECT Cell adhesive protein binding involved in bundle of His 
cell-Purkinje myocyte communication
5.30E-03
Annotation cluster 5
GOTERM_CC_DIRECT Haptoglobin-hemoglobin complex 2.43E-05
GOTERM_CC_DIRECT Endocytic vesicle lumen 1.71E-04
GOTERM_MF_DIRECT Haptoglobin binding 1.10E-03
GOTERM_BP_DIRECT Positive regulation of cell death 1.90E-02
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Category GO term p-value
GOTERM_CC_DIRECT Hemoglobin complex 1.97E-02
GOTERM_MF_DIRECT Oxygen transporter activity 2.90E-02
GOTERM_BP_DIRECT Oxygen transport 3.43E-02
Annotation cluster 6
GOTERM_BP_DIRECT SRP-dependent cotranslational protein targeting to 
membrane
9.85E-05
GOTERM_BP_DIRECT Nuclear-transcribed mRNA catabolic process, nonsense-
mediated decay
5.83E-04
GOTERM_BP_DIRECT Viral transcription 1.69E-03
GOTERM_BP_DIRECT Translational initiation 5.82E-03
GOTERM_CC_DIRECT Ribosome 3.40E-02
Annotation cluster 7
GOTERM_MF_DIRECT Voltage-gated anion channel activity 5.30E-03
GOTERM_MF_DIRECT Porin activity 5.30E-03
GOTERM_CC_DIRECT Pore complex 1.11E-02
GOTERM_BP_DIRECT Anion transport 3.02E-02
GOTERM_BP_DIRECT Regulation of anion transmembrane transport 4.34E-02
Annotation cluster 8
GOTERM_BP_DIRECT Daunorubicin metabolic process 1.00E-02
GOTERM_BP_DIRECT Doxorubicin metabolic process 1.00E-02
Annotation cluster 9
GOTERM_BP_DIRECT Nucleotide-excision repair, DNA damage recognition 1.00E-02
GOTERM_BP_DIRECT Global genome nucleotide-excision repair 2.47E-02
Annotation cluster 10
GOTERM_MF_DIRECT Neutral amino acid transmembrane transporter activity 1.82E-02
GOTERM_BP_DIRECT Neutral amino acid transport 2.62E-02
Table 2. 
The functional categories of 400 DUPs, identified with GO enrichment analysis. Modified from Lu et al. [19], 
with permission from Springer publisher open access article, copyright 2020.
through lysine-63 linkages showed an auto-regulatory mechanism controlling ITCH 
cytoplasmic-nuclear shuffling [24]. Therefore, the effects of the currently known 
ubiquitination on these enzymes are only the tip of the iceberg. However, one should 
also realize that this study found ubiquitination of cullin proteins such as Cul4A and 
Cul5, while cullin proteins can also be modified by NEDD8 to form NEDDylation. 
It is well known that the use of the K-ε-GG antibody cannot discriminate between 
proteins modified with ubiquitin and the related proteins NEDD8 and ISG15. 
Therefore, for deep investigation of this identified ubiquitination of E3s Cul4A and 
Cul5 in LUSC in the future, additional experiments are needed to discriminate E3s 
Cul4A and Cul5 that were modified by ubiquitin, NEDD8, or ISG15 [22].
Proteasome was a pivotal component for ubiquitin-mediated proteolysis. The 
26S proteasome was a complex including two 19S regulatory particles (PA700) and 
one 20S core particle. The 20S degradation complex contained two α rings (7 sub-
units, α1-α7) and two β rings (7 subunits, β1-β7). These α rings and β rings together 
formed a hollow ground circle. The tube-like structure was highly conserved 
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from archaea to mammals [25]. Among them, the α ring was located in the outer 
layer of the cylinder-like structure, which mainly acted on the recognition of the 
substrate; the β ring was located in the inner layer of the cylinder-like structure, 
and was mainly responsible for catalyzing the degradation of the substrate [26, 27]. 
Three subunits that played a catalytic role were located on the inner surface of the 
β-ring molecule, exhibiting cysteine protease-like activity, trypsin-like activity, 
and chymotrypsin-like activity [26, 27]. The 19S regulatory complex contained 19 
different subunits, which were divided into two parts: “base” and “lid” [28]. Among 
them, the base part formed the proximal part of the 19S regulatory complex, which 
was connected to the alpha ring of the 20S degradation complex, and the lip part 
formed the distal end. The base section contained 6 ATPase-dependent subunits 
(Rpt1-Rpt6) and 2 ATPase-independent subunits (Rpn1 and Rpn2) [28]. Usually, 
Rpn10 and Rpn13 were also classified as the base [26]. The lid part consisted of 
Rpn3, Rpn5-Rpn9, and Rpn11-Rpn12 subunits [28]. The 19S regulatory complex 
recognized ubiquitin-labeled target proteins (Rpn10 and Rpn13) and before the 
target protein entered the 20S degradation complex, deubiquitinated the target 
protein (Rpn11) and opened the folded structure of the target protein [28]. This 
study discovered five UPs (Rpn3, Rpn5, Rpn6, Rpn10, and Rpn12) in PA700 (Lid), 
and seven UPs (Rpn13, Rpt1, Rpt2, Rpt3, Rpt4, Rpt5, and Rpt6) in PA700 (Base) in 
LUSC. No UPs were identified in 20S core particle in LUSC (Figure 4).
Figure 2. 
Statistically significant KEGG pathways enriched from 627 UPs. Those UPs were significantly enriched in 
47 KEGG pathways (p < 0.05 and FDR < 0.05), among which were included two UPS-related pathways—
ubiquitin-mediated proteolysis pathway (hsa04120) and proteasome complex (hsa03050). The darker dot 
means the more significant enrichment, and the size of the dot represents the number of UPs enriched in 
the pathway.
Ubiquitin - Proteasome Pathway
10
3.4 DUPs involved in UPS-related molecular network alternations in LUSC
KEGG pathway network analysis of 400 DUPs revealed 39 statistically significant 
ubiquitination-mediated signaling pathway alterations (P < 0.05 and FDR < 0.05) 
(Figure 5), including one UPS-related pathway – proteasome complex (hsa03050).
Figure 3. 
UPs identified in ubiquitin-mediated proteolysis pathway (hsa04120). Pink rectangle means the ubiquitinated 
proteins, and green rectangle means nonubiquitinated proteins. The pathway node in the right panel 
corresponds to the pink rectangle in the left diagram. Protein access number is the Swiss-Prot accession number. 
Modified sites refer to ubiquitinated lysine (K). Ratio (T/N) = ratio of tumors to controls. Asterisk (*) 
represents there is no quantitative intensity on this modification site in both the tumor and the control group.
Figure 4. 
UPs identified in proteasome complex (hsa03050). Pink rectangle means the ubiquitinated subunits, and green 
rectangle means non-ubiquitinated subunits. The pathway node in the right panel corresponds to the pink 
rectangle in the left diagram. Protein access number is the Swiss-Prot accession number. Modified sites refer to 
ubiquitinated lysine (K). Ratio (T/N) = ratio of tumors to controls. T+/N− indicates that this modification 
site has quantitative intensity only in tumor group, while T−/N+ means this modification site has quantitative 
intensity only in control group. Asterisk (*) represents there is no quantitative intensity on this modification site 
in both the tumor and the control group.
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In proteasome complex, this study discovered 4 DUPs (Rpn3, Rpn5, Rpn10, and 
Rpn6) in PA700 (Lid), and 7 DUPs (Rpn13, and Rpt1-Rpt6) in PA700 (Base). Their 
ubiquitination levels were significantly increased at residues K74 (Ratio = 5.16) in 
Rpn10, K34 (Ratio = 2.27) in Rpn13, K293 (T+/N−) in Rpt2, K46 (Ratio = 4.96) in 
Rpt1, K372 (T+/N−) in Rpt5, K273 (T+/N−) in Rpt4, K346 (T+/N−), K330 (T+/N−) 
and K290 (T+/N−) in Rpt6, K194 (T+/N−), K328 (T+/N−) and K62 (Ratio = 2.37) in 
Rpt4, K273 (T+/N−) in Rpn3, K32 (T+/N−) in Rpn6, and K147 (T+/N−) in Rpn5. The 
ubiquitination level was decreased at residue K53 (Ratio = 0.33) in Rpt5 (Figure 6).
The proteasome was a pivotal component of UPS to degrade the short-lived 
regulatory proteins and remove the damaged soluble proteins [29]. Consequently, 
dysfunction of proteasome might decrease the capability of protein degrada-
tion, thus resulting in the increased level of misfolded and damaged proteins, 
which was closely related to tumorigenesis [30]. The 26S proteasome had one 20S 
subunit and two 19S regulatory caps. Two 19S caps were necessary to maintain the 
normal functions of 20S subunit. For example, Rpn 13 in 19S base cap and Rpn 
10 in 19S head cap were the recognition-receptors of the ubiquitinated proteins 
[31, 32]. Further, PTMs (such as phosphorylation, acetylation, myristoylation, 
and ubiquitination) had been detected in those subunits to greatly complicate 
the mechanisms of the modulation of proteasome activity. For example, Rpn 
10 was mono-ubiquitinated to recruit substrate protein and interact with the 
shuttle factor of proteasome in drosophila [33, 34]. The multiple ubiquitinations 
in 19S cap of proteasome such as Rpn 1, Rpn 10, and Rpn 13 were necessary to 
autophage proteasome [35]. Our study [19] discovered three non-ATPase subunits 
Figure 5. 
Statistically significant KEGG pathways enriched from 400 DUPs. Those DUPs were significantly enriched in 
39 KEGG pathways (p < 0.05 and FDR < 0.05), including one UPS-related pathway – proteasome complex. 
The darker dot means the more significant enrichment, and the size of the dot represents the number of DUPs 
enriched in the pathway. Reproduced from Lu et al. [19], with permission from Springer publisher open access 
article, copyright 2020.
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(PSMD3, PSMD11, and PSMD12), and three ATPase subunits (PSMC1, PSMC4, 
and PSMC6) were differentially ubiquitinated in 19S regulatory cap of protea-
some in LUSC tissues. It clearly demonstrated that these ubiquitinations in 19S 
regulatory caps might influence the structure and functions of the proteasome 
complex. Some studies found that PSMD11 was necessary to assemble proteasome 
complex and elevate the activity of proteasome in embryonic stem cells [36]. 
Acetylation [37], phosphorylation [38], and SUMO [39] had been reported to 
occur in PSMD11, and our study first discovered that PSMD11 was ubiquitinated 
at residue K32 in LUSC tissues but not in control lung tissues [19]. Currently, few 
literature studies are found regarding the study on the relationship of ubiquitina-
tion and function of proteasome subunits. However, the abnormal ubiquitination 
of proteasome subunits might cause the functional abnormalities of proteasome 
complex in LUSC tissues and further lead to the imbalance of synthesis and degra-
dation of intracellular proteins. These findings offer the new clues to deeply study 
and understand the regulation of UPS functions in LUSC.
4. Conclusions
Label-free quantitative ubiquitinomics was an effective approach to identify 
ubiquitinated proteins and ubiquitination sites and quantifies the levels of ubiqui-
tination in human LUSC tissues. In total, 627 UPs and 400 DUPs were identified, 
providing the first (differential) ubiquitinome profile based on fresh human LUSC 
tissues. GO and KEGG analyses of UPs and DUPs revealed the statistically signifi-
cant ubiquitination-mediated molecular network alternations, among which several 
proteins in two UPS-related pathways (ubiquitin-mediated proteolysis pathway, 
and proteasome complex) underwent ubiquitination in LUSC. Furthermore, 11 
Figure 6. 
DUPs identified in proteasome complex (hsa03050). The red rectangle means the intensities of all identified 
ubiquitination sites in one protein were increased, and yellow rectangle means at least two ubiquitination sites 
in a protein with inconsistent ubiquitination intensities. The pathway node in the right panel corresponds to 
the red and yellow rectangle in the left diagram. Protein access number is the Swiss-Prot accession number. 
Modified sites refer to ubiquitinated lysine (K). Ratio (T/N) = ratio of tumors to controls. T+/N− indicates that 
this modification site has quantitative intensity only in tumor group, while T−/N+ means this modification site 
has quantitative intensity only in control group. Reproduced from Lu et al. [19], with permission from Springer 
publisher open access article, copyright 2020.
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subunits of proteasome complex were differentially ubiquitinated in LUSC. These 
findings demonstrated that ubiquitination was widely present in UPS in LUSC. At 
the same time, abnormal ubiquitination might affect the functions of the protea-
some to promote tumorigenesis and development. This book chapter focused 
on the status of protein ubiquitination in UPS-related pathways in human LUSC 
tissues, and provided the scientific data for the elucidation of the specific molecular 
mechanisms of abnormal ubiquitination during canceration and the development 
of anti-tumor drugs targeting UPS for lung cancer.
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